Rivoceranib
Rivoceranib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit, tyrosine-protein kinase CSK, and vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
528 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 7 | 82 | 15 | 2 | 13 | 112 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 10 | 55 | 15 | 3 | 12 | 83 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 7 | 48 | 12 | 1 | 14 | 73 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 7 | 41 | 9 | 1 | 6 | 56 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 30 | 7 | 2 | 5 | 44 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 30 | 7 | 1 | 2 | 40 |
| Adenocarcinoma | D000230 | — | — | 8 | 27 | 5 | 1 | 2 | 37 |
| Neoplasms | D009369 | — | C80 | 15 | 15 | 1 | 3 | 2 | 33 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 22 | — | 1 | — | 25 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 16 | 4 | 1 | 1 | 23 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 6 | 42 | 7 | — | 11 | 57 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 16 | 4 | — | 1 | 22 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 15 | 4 | — | 2 | 22 |
| Colorectal neoplasms | D015179 | — | — | 4 | 17 | 1 | — | 2 | 21 |
| Triple negative breast neoplasms | D064726 | — | — | 4 | 16 | 2 | — | — | 20 |
| Recurrence | D012008 | — | — | — | 15 | 1 | — | 3 | 19 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 11 | 2 | — | 1 | 13 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | 10 | 2 | — | — | 13 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | 10 | 2 | — | — | 13 |
| Osteosarcoma | D012516 | — | — | — | 9 | 1 | — | 1 | 10 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | 15 | — | — | — | 16 |
| Sarcoma | D012509 | — | — | 1 | 13 | — | — | 1 | 15 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 9 | — | — | 2 | 11 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 10 | — | — | — | 10 |
| Neoadjuvant therapy | D020360 | — | — | — | 8 | — | — | 1 | 9 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 7 | — | — | — | 8 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 7 | — | — | — | 7 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 5 | — | — | 1 | 6 |
| Adenocarcinoma of lung | D000077192 | — | — | 1 | 4 | — | — | — | 5 |
| Head and neck neoplasms | D006258 | — | — | 1 | 4 | — | — | — | 4 |
Show 44 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 2 | 2 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Adjuvant chemotherapy | D017024 | — | — | — | — | — | — | 1 | 1 |
| Fatal outcome | D017809 | — | — | — | — | — | — | 1 | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 1 | 1 |
| Chondrosarcoma | D002813 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rivoceranib |
| INN | rivoceranib |
| Description | Apatinib, also known as rivoceranib, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically, apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
|
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1218779-75-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3186534 |
| ChEBI ID | — |
| PubChem CID | 11315474 |
| DrugBank | DB14765 |
| UNII ID | 5S371K6132 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,359 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,007 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use